Laule Michael, Meisel Christian, Prauka Ines, Cascorbi Ingolf, Malzahn Uwe, Felix Stephan B, Baumann Gert, Roots Ivar, Stangl Karl, Stangl Verena
Medizinische Klinik mit Schwerpunkt Kardiologie, Angiologie, Pneumologie, Charité, Campus Mitte, Humboldt-Universität, Schumannstrasse 21/21, 10117 Berlin, Germany.
J Mol Med (Berl). 2003 May;81(5):305-9. doi: 10.1007/s00109-003-0433-z. Epub 2003 Apr 2.
We have recently shown that high CA repeat copy numbers (> or = 34 repeats) in intron 13 of the endothelial nitric oxide (eNOS) gene are associated with excess risk of coronary artery disease. Hyperhomocysteinemia interacts by several mechanisms with the NO system, thereby favoring endothelial dysfunction. Since hyperhomocysteinemia evidently promotes prothrombotic activation, we investigated a possible interaction among hyperhomocysteinemia, the eNOS CA repeat polymorphism, and acute coronary syndromes. The median value of homocysteine in our study population was 9.4 micromol/l. We accordingly determined the relative risk of acute coronary syndromes for homocysteine values higher than 9.4 micromol/l and 9.4 micromol/l or lower in the entire coronary artery disease group, and at different CA repeat cutoff values (34, 35, 36, 37, 38 CA repeats). For the entire coronary artery disease group ( n=1000), homocysteine levels higher than 9.4 micromol/l were not significantly associated with acute coronary syndromes. Although the CA repeat copy numbers were not associated with acute coronary syndromes in the overall group, the relative risk among women with homocysteine higher than 9.4 micromol/l for developing acute coronary syndromes increased nonsignificantly from 0.98 at cutoff 34 CA repeats to 1.68 at 35 CA repeats and significantly to 4.89 at 36 CA repeats, 11.20 at 37 CA repeats, and 18.32 at 38 CA repeats. This effect modification was not observed in men. These data suggest gender-specific gene-environment interaction between the CA repeat eNOS polymorphism and homocysteine in acute coronary syndromes.
我们最近发现,内皮型一氧化氮(eNOS)基因第13内含子中的高CA重复拷贝数(≥34次重复)与冠状动脉疾病的额外风险相关。高同型半胱氨酸血症通过多种机制与一氧化氮系统相互作用,从而促进内皮功能障碍。由于高同型半胱氨酸血症明显促进血栓前激活,我们研究了高同型半胱氨酸血症、eNOS CA重复多态性与急性冠状动脉综合征之间可能的相互作用。我们研究人群中同型半胱氨酸的中位数为9.4微摩尔/升。因此,我们确定了整个冠状动脉疾病组中同型半胱氨酸值高于9.4微摩尔/升和9.4微摩尔/升及以下时急性冠状动脉综合征的相对风险,以及在不同的CA重复截断值(34、35、36、37、38次CA重复)时的相对风险。对于整个冠状动脉疾病组(n = 1000),同型半胱氨酸水平高于9.4微摩尔/升与急性冠状动脉综合征无显著关联。虽然CA重复拷贝数在总体组中与急性冠状动脉综合征无关,但同型半胱氨酸高于9.4微摩尔/升的女性发生急性冠状动脉综合征的相对风险从CA重复截断值为34时的0.98无显著增加到35时的1.68,并在36时显著增加到4.89,37时为11.20,38时为18.32。在男性中未观察到这种效应修饰。这些数据表明,在急性冠状动脉综合征中,CA重复eNOS多态性与同型半胱氨酸之间存在性别特异性的基因-环境相互作用。